{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04081103",
            "orgStudyIdInfo": {
                "id": "NEX-PED-005"
            },
            "organization": {
                "fullName": "Amber Ophthalmics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries",
            "officialTitle": "A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled Study to Assess the Efficacy and Safety of Nexagon\u00ae (NEXAGON) Applied Topically in Subjects With Corneal Persistent Epithelial Defects Resulting From Severe Ocular Chemical and/or Thermal Injuries",
            "acronym": "EXPEDE",
            "therapeuticArea": [
                "Other"
            ],
            "study": "nexagon-for-the-treatment-of-corneal-persistent-epithelial-defects-following-severe-ocular-chemical-and-or-thermal-injuries"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-08",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2020-06-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-08-29",
            "studyFirstSubmitQcDate": "2019-09-04",
            "studyFirstPostDateStruct": {
                "date": "2019-09-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-08-25",
            "lastUpdatePostDateStruct": {
                "date": "2022-08-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Amber Ophthalmics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon\u00ae (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least a further 28 days."
        },
        "conditionsModule": {
            "conditions": [
                "Corneal Persistent Epithelial Defect"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 108,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Nexagon\u00ae (lufepirsen) High Dose Concentration",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Nexagon\u00ae (lufepirsen) High Dose Concentration",
                        "Drug: Open-label Nexagon\u00ae (lufepirsen)"
                    ]
                },
                {
                    "label": "Nexagon\u00ae (lufepirsen) Low Dose Concentration",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Nexagon\u00ae (lufepirsen) Low Dose Concentration",
                        "Drug: Open-label Nexagon\u00ae (lufepirsen)"
                    ]
                },
                {
                    "label": "Vehicle",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Vehicle",
                        "Drug: Open-label Nexagon\u00ae (lufepirsen)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nexagon\u00ae (lufepirsen) High Dose Concentration",
                    "description": "Nexagon\u00ae (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.",
                    "armGroupLabels": [
                        "Nexagon\u00ae (lufepirsen) High Dose Concentration"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nexagon\u00ae (lufepirsen) Low Dose Concentration",
                    "description": "Nexagon\u00ae (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.",
                    "armGroupLabels": [
                        "Nexagon\u00ae (lufepirsen) Low Dose Concentration"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vehicle",
                    "description": "Vehicle is administered topically in the affected eye three (3) times over 28 days.",
                    "armGroupLabels": [
                        "Vehicle"
                    ],
                    "otherNames": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Open-label Nexagon\u00ae (lufepirsen)",
                    "description": "Open-label Nexagon\u00ae (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.",
                    "armGroupLabels": [
                        "Nexagon\u00ae (lufepirsen) High Dose Concentration",
                        "Nexagon\u00ae (lufepirsen) Low Dose Concentration",
                        "Vehicle"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The proportion of subjects achieving corneal epithelial recovery, as assessed by slit lamp examination.",
                    "description": "Corneal epithelial recovery, defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days, will be assessed by slit lamp examination.",
                    "timeFrame": "Up to 56 days."
                },
                {
                    "measure": "Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0",
                    "description": "Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0.",
                    "timeFrame": "Up to 30 days after last application of intervention"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to corneal epithelial recovery, as assessed by slit lamp examination.",
                    "description": "The time (number of days) from randomization to the time of initial re-epithelialization for a cornea that remains re-epithelialized and durable for at least 28 days will be recorded following confirmation by slit lamp examination.",
                    "timeFrame": "Within 28 days"
                },
                {
                    "measure": "Improvement from baseline of visual acuity measured by the Snellen scale.",
                    "description": "Improvement of visual acuity on the Snellen scale from baseline until study exit will be measured.",
                    "timeFrame": "Up to 56 days"
                },
                {
                    "measure": "The number of NEXAGON treatment doses required to achieve recovery of the corneal epithelium will be assessed.",
                    "description": "The number of NEXAGON dose applications required to achieve corneal epithelial recovery will be recorded. Corneal epithelial recovery is defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days and will be confirmed by slit lamp examination.",
                    "timeFrame": "Within 56 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female of any age.\n2. The presence of a non-infected, corneal persistent epithelial defect (PED) which has resulted from a severe chemical and/or thermal (burn) injury to one or both eyes.\n3. The PED is non-responsive to current standard of care for at least 14 days from injury.\n4. The PED measures at least 2 mm along the largest diameter at Day 1 of the Treatment Period.\n5. Providing written informed consent and ability to comply with the visit and dosing schedule.\n\nExclusion Criteria:\n\n1. Subjects who will be unlikely to tolerate the wearing of a Bandage Contact Lens.\n2. Have active ocular infection.\n3. Subjects with corneal perforation or impending corneal perforation.\n4. Subjects with any other past or present ophthalmic disease or medical condition that, in the Investigator's opinion, may affect the safety of the subject or the outcome of the study.\n5. Subjects receiving systemic corticosteroids (equivalent to GREATER THAN 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days and will remain unchanged during the study.\n6. Subjects being treated with systemic corticosteroids (equivalent to \\>10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days prior to Day 1.\n7. Subjects with severe lid abnormalities or ocular conditions that contribute to the persistence of the epithelial defect.\n8. Female subjects of childbearing potential who are pregnant, nursing, planning a pregnancy or not using an adequate and medically acceptable form of birth control.\n9. Subjects who have participated in an interventional clinical trial within 30 days prior to Day 1.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "President and CSO, PharmD",
                    "role": "CONTACT",
                    "phone": "(858) 663-1500",
                    "email": "clinical@amberophthalmics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Jules Stein Eye Institute",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ellen Pascual",
                            "role": "CONTACT",
                            "phone": "310-794-5592",
                            "email": "pascual@jsei.ucla.edu"
                        },
                        {
                            "name": "Anthony Aldave, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Colorado Eye Consultants",
                    "status": "RECRUITING",
                    "city": "Littleton",
                    "state": "Colorado",
                    "zip": "80120",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shivam Patel",
                            "role": "CONTACT",
                            "phone": "303-730-0404",
                            "email": "spatel@corneaonline.com"
                        },
                        {
                            "name": "S. Lance Forstot, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.61332,
                        "lon": -105.01665
                    }
                },
                {
                    "facility": "Cincinnati Eye Institute",
                    "status": "RECRUITING",
                    "city": "Edgewood",
                    "state": "Kentucky",
                    "zip": "41017",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katie Hogeback",
                            "role": "CONTACT",
                            "phone": "859-331-9000",
                            "phoneExt": "4517",
                            "email": "khogeback@cvphealth.com"
                        },
                        {
                            "name": "Edward Holland, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.01867,
                        "lon": -84.58189
                    }
                },
                {
                    "facility": "University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joshua Hou, MD",
                            "role": "CONTACT",
                            "phone": "612-626-1442",
                            "email": "jhhou@umn.edu"
                        },
                        {
                            "name": "Joshua Hou, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Mercy Eye Care",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Missouri",
                    "zip": "65804",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Diana Connelly",
                            "role": "CONTACT",
                            "phone": "417-820-7493",
                            "email": "diana.connelly@mercy.net"
                        },
                        {
                            "name": "Zachary Seagrave, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.21533,
                        "lon": -93.29824
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}